Mental Health Clinics in Greenville, FL Accepting Medicare
6 Mental Health Clinics found. Showing 1 - 6
 Greenville Outpatient Services, Inc. Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 437 Nw Jackrabbit Loop, Greenville, FL 32331 Phone: 954-536-9539 |
Tranquility Now Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 123 Sw Odessa Ter, Greenville, FL 32331 Phone: 850-556-3698 |
Honey Lake Clinic Inc Clinic - Adolescent and Children Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1450 Nw Honey Lake Rd, Greenville, FL 32331 Phone: 954-536-9539 |
Honey Lake Clinic Inc Clinic - Adult Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1449 Nw Honey Lake Rd, Greenville, FL 32331 Phone: 954-536-9539 |
Disc Village, Inc. Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 1476 Sw Main St, Greenville, FL 32331 Phone: 850-948-1231 Fax: 850-948-1230 |
Greenville Hills Academy Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 742 Sw Greenville Hills Rd, Greenville, FL 32331 Phone: 850-948-1200 |
News Archive
Study examines how mice with genetic bone defects respond to infusions of BMMSC
A new study in Nature Medicine describes how different types of immune system T-cells alternately discourage and encourage stem cells to regrow bone and tissue, bringing into sharp focus the importance of the transplant recipient's immune system in stem cell regeneration.
Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI
Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury.
Champions Biotechnology expands collaboration to accelerate oncology drug development
Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an agreement with Ortho Biotech Oncology Research & Development, a Division of Janssen Pharmaceutica NV, for the evaluation of a novel preclinical oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG
Vanda Pharmaceuticals Inc. announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada. Fanapt(TM) was approved by the U.S. Food and Drug Administration on May 6, 2009 for the acute treatment of schizophrenia in adults.
› Verified 8 days ago